Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Immunosuppression Drug Could Reduce Chemotherapy Resistance
Disease Discoveries

Immunosuppression Drug Could Reduce Chemotherapy Resistance

By Will DossJun 16, 2021
Share
Facebook Twitter Email
Roger Stupp, MD, the Paul C. Bucy Professor of Neurological Surgery and Priya Kumthekar, MD, ’11 ’12 GME, associate professor in the Ken and Ruth Davee Department of Neurology Division of Neuro-Oncology, were co-authors of the study published in Brain. Atique Ahmed, PhD, associate professor of Neurological Surgery, was senior author.

A drug currently used to prevent organ rejection in transplants could also reduce chemotherapy resistance in glioblastoma, according to a Northwestern Medicine study published in Brain.

The drug prevents glioblastoma cells from using molecular plasticity to circumvent chemotherapy, and Northwestern Medicine investigators are currently working to translate these findings to the clinic, according to Atique Ahmed, PhD, associate professor of Neurological Surgery and senior author of the study.

“These cancer cells are very adaptable, and this is one reason why they resist our current therapies,” said Ahmed. “Because we are repurposing an already approved drug, this could speed up the clinical testing.”

ARL13B (in green) expression in the cilia-like structure (arrow) of the glioblastoma cells (blue cell nucleus).

Glioblastoma is a particularly deadly brain cancer, and patients usually have a short life expectancy after diagnosis. The current standard of care is surgical resection, radiation and chemotherapy.

Among the most effective chemotherapy drugs for glioblastoma is temozolomide, which corrupts purine molecules in cancer cells. Purine is essential for DNA synthesis, so cells attempting to use this “bad” purine will eventually die. However, glioblastoma cells are extraordinarily adaptable, allowing them to accumulate resistance to the therapy, according to Ahmed.

“They can acquire a different form and shape at the molecular level based on their microenvironment,” Ahmed said. “Once they’ve gained this resistance, the cancers comes back and is often very aggressive.”

In the study, Ahmed and his collaborators analyzed the epigenetic profile of glioblastoma cells being treated with temozolomide, finding that specific genes are modulated during therapy. One gene that is modulated, ARL13B, is known for its role in cilia. In this case, the gene helps cancer cells process their own purine, blocking the tainted purine from harming the cancer cells.

“They make fresh purine and they can avoid the purine damaged by chemotherapy,” Ahmed said.

Inhibiting an ARL13B pathway in experiments forced glioblastoma cells to rely on the damaged purine, and this pathway can be blocked with a previously developed drug: mycophenolate mofetil. An immunosuppressive medication usually used in organ transplants, the drug blocks glioblastoma cells to produce fresh purine and rely on the damaged purine. When combined with chemotherapy in models of glioblastoma, mycophenolate mofetil enhanced the therapeutic efficacy of temozolomide.

The fact that mycophenolate mofetil is already approved should speed translation from bench to bedside, according to Priya Kumthekar, MD, ’11 ’12 GME, associate professor in the Ken and Ruth Davee Department of Neurology Division of Neuro-Oncology and a co-author of the study.

“Repurposing of drugs, as opposed to new drugs, allows for faster development of its use in any given disease as the safety profile in humans is much better understood,” said Kumthekar, who is also an associate professor of Medicine in the Division of Hematology and Oncology.

This work was supported by the National Institute of Neurological Disorders and Stroke grants 1R01NS096376, R01NS095642 and 1R01NS112856; American Cancer Society grant RSG-16-034-01-DDC,; National Institute of Cancer grant R00CA194192; National Institute of Medicine grants R01GM135587 and R35CA197725, and P50CA221747 SPORE for Translational Approaches to Brain Cancer.

Co-authors of the study include Issam Ben-Sahra, PhD, assistant professor of Biochemistry and Molecular Genetics; Craig Horbinski, MD, PhD, director of Neuropathology in the Department of Pathology; Maciej Lesniak, MD, the chair and Michael J. Marchese Professor of Neurosurgery; Jason Miska, PhD, research assistant professor of Neurological Surgery; C. David James, PhD, the Jean Malnati Miller Professor of Brain Tumor Research and vice chair for research in the Department of Neurological Surgery and Roger Stupp, MD, the Paul C. Bucy Professor of Neurological Surgery, chief of Neuro-Oncology in the Department of Neurology and a professor of Medicine in the Division of Hematology and Oncology.

Ahmed, Kumthekar, Ben-Sahra, Horbinski, James, Lesniak, Miska and Stupp are members of the Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Cancer Neurology and Neuroscience Research
Share. Facebook Twitter Email

Related Posts

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023

Lieber Receives VA Rehabilitation Research and Development Award 

Mar 13, 2023

Comments are closed.

Latest News

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023

Future Directions in Continuing Medical Education

Mar 14, 2023

Lieber Receives VA Rehabilitation Research and Development Award 

Mar 13, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
_5NM1245
230204_SERIO_MANDELL_Feinberg_Formal_0928
_5NM1715
_5NM0526
_5NM1026 (1)
_5NM1906
_5NM2173
230204_SERIO_MANDELL_Feinberg_Formal_0896
230204_SERIO_MANDELL_Feinberg_Formal_1113
230204_SERIO_MANDELL_Feinberg_Formal_1868
230204_SERIO_MANDELL_Feinberg_Formal_1237
230204_SERIO_MANDELL_Feinberg_Formal_1172

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.